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Introduction
Kidney transplantation is acknowledged as the treatment 
of choice for people with end- stage kidney failure, but 
the need for lifelong antirejection therapy to prevent allo-
graft failure is associated with the development of 
immunosuppression- related complications [1]. One of the 
major complications after kidney transplantation is the 
development of cancer, and the similarity of (infection- 
related) cancer development between kidney allograft 
recipients and patients with HIV/AIDS suggesting immune 
deficiency, rather than other risk factors, contributes to 
increased cancer rates after kidney transplantation [2]. 
Cancer is one of the greatest concerns for kidney allograft 
recipients themselves [3], is associated with increased cost 
[4], and is linked to increased incidence and mortality 
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Abstract
Administrative data are frequently used for epidemiological studies but its use-
fulness to analyze cancer epidemiology after kidney transplantation is unclear. 
In this retrospective population- based cohort study, we identified every adult 
kidney- alone transplant performed in England (2003–2014) using administrative 
data from Hospital Episode Statistics. Results were compared to the hospitalized 
adult general population in England to calculate standardized incidence and 
mortality ratios. Data were analyzed for 19,883 kidney allograft recipients, with 
median follow- up 6.0 years’ post- transplantation. Cancer incidence was more 
common after kidney transplantation compared to the general population in 
line with published literature (standardized incidence ratio 2.47, 95% CI: 2.34–
2.61). In a Cox proportional hazards model, cancer development was associated 
with increasing age, recipients of deceased kidneys, frequent readmissions within 
12 months post- transplant and first kidney recipients. All- cause mortality risk 
for kidney allograft recipients with new- onset cancer was significantly higher 
compared to those remaining cancer- free (42.0% vs. 10.3%, respectively). How-
ever, when comparing mortality risk for kidney allograft recipients to the general 
population after development of cancer, risk was lower for both cancer- related 
(standardized mortality ratio 0.75, 95% CI: 0.71–0.79) and noncancer- related 
mortality (standardized mortality ratio 0.90, 95% CI: 0.85–0.95), which contra-
dicts reported literature. Although some plausible explanations are conceivable, 
our analysis likely reflects the limitations of administrative data for analyzing 
cancer data. Future studies require record linkage with dedicated cancer registries 
to acquire more robust and accurate data relating to cancer epidemiology after 
transplantation.
Cancer Medicine
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in population cohort studies [5–13]. This makes it impera-
tive to understand cancer development, and its risk for 
progression, if we are to improve long- term outcomes 
after kidney transplantation.
Cancer- related mortality has been shown to be higher 
among kidney allograft recipients compared to the general 
population in cohorts from England [6] and Ontario, 
Canada [13], although equivalent cancer- related mortality 
was observed in a US cohort [5]. Some methodological 
considerations limit interpretation of such data. Firstly, 
analysis of cancer- related mortality was not always under-
taken specifically among the cancer incident cohort. This 
is important as reporting risk for cancer- related mortality 
in isolation will be skewed by increased incidence. Secondly, 
risk for cancer versus noncancer death among kidney 
allograft recipients after developing cancer is often over-
looked. This is important because increased rates of cancer 
incidence after transplantation may not directly lead to 
cancer- linked mortality as competing risks for death occur 
after kidney transplantation in the context of immuno-
suppression (e.g., cardiovascular events or infection).
The use of administrative data for research studies is cham-
pioned in the setting of solid organ transplantation [14]. With 
ready access to national administration data for secondary 
care (i.e., hospital) episodes, we were keen to explore the 
usefulness of utilizing such data to explore cancer outcomes 
after kidney transplantation. Therefore, we undertook a popu-
lation cohort study to explore cancer incidence and subsequent 
progression to mortality (cancer vs. noncancer) among kidney 
allograft recipients in England compared to the general hos-
pitalized population using national administrative data.
Materials and Methods
Study population
We obtained data for every kidney- alone transplant pro-
cedure performed in England between 2003 and 2014, 
collecting patient demographics that were recorded at the 
time of admission for kidney transplantation. Data were 
obtained from Hospital Episode Statistics (HES) [15], an 
administrative data warehouse containing admissions to 
all National Health Service hospitals in England. It con-
tains detailed records relating to individual patient treat-
ments, with data extraction facilitated utilizing codes on 
procedural classifications (Office of Population Censuses 
and Surveys Classification of Interventions and Procedures, 
4th revision [OPCS- 4]) [16] and medical classifications 
(World Health Organization International Classification 
of Disease, 10th revision [ICD- 10]) [17].
This study included all kidney- alone transplant proce-
dures (OPCS- 4 codes; M01) performed over the study 
time period. Cancer was defined from ICD- 10 codes 
C00- C99 (excluding nonmelanoma skin cancer (C44)) 
post- transplantation. As HES represents secondary care 
administrative data, any diagnosis of cancer not involving 
admission to hospital would not be captured. With regard 
to outcome analysis, the HES dataset is limited to only 
capturing deaths occurring in a hospital setting. Therefore, 
we linked our HES cohort with mortality data from the 
Office for National Statistics (ONS) [18], which collects 
information on all registered deaths in the United Kingdom. 
This study did not require institutional review board 
approval due to the pseudoanonymized nature of the data 
retrieved—data were linked by NHS Informatics using 
deterministic methodology using special HES ID codes and 
avoided patient identifiable data. We registered this project 
as an audit with University Hospitals Birmingham NHS 
Trust (audit identifier; CARMS- 12578). This study is 
reported in accordance with the RECORD (REporting of 
studies Conducted using Observational Routinely collected 
health Data) statement [19].
Data inclusion
We excluded the following transplant recipients from analysis; 
missing age or sex, residence outside England, combined 
solid organ transplant, pretransplant history of cancer, and 
pediatric cases (aged under 18 years). Our comparative 
general population cohort comprised of all adults (aged 18 
and over) admitted to an English hospital with a diagnosis 
of cancer, excluding those with a previous history of cancer 
or a solid organ transplant. Results from HES with less 
than five cases were not numerically identified and were 
classed as too small to report to avoid potential patient 
identifiability (in accordance with data agreement).
Statistical analysis
Primary outcome measures were cancer incidence after 
kidney transplantation and risk for cancer versus noncancer 
mortality. Standardized incidence ratios were obtained using 
the indirect standardization method, with age-, sex-, and 
cancer-specific specific rates from ONS life tables of the 
general population, to measure the risk of cancer incidence 
in the transplant cohort compared to the general popula-
tion. Standardized mortality ratios were calculated using 
cancer patients only from the transplant and general popu-
lation cohorts. We utilized the indirect standardization 
method, using age-, sex-, and cancer-specific rates from 
the general population cohort, to measure the risk of cancer 
or noncancer mortality in the transplant versus general 
population cohorts (with 95% confidence intervals). The 
general population cohort was defined as patients admitted 
to hospital between 2003 and 2014, with no recorded solid 
organ transplantation or previous history of cancer.
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Unadjusted survival analyses were performed with the 
generation of Kaplan–Meier plots with log- rank test used 
for comparative analysis. We conducted Cox regression 
analysis to examine risk factors for post- transplant cancer 
after adjustment for; age, sex, ethnicity, type of donor, 
number of readmissions in the first year post- transplant, 
delayed graft function, Charlson comorbidity score, and 
whether they had a repeat kidney transplant or not. A 
P- value <0.05 was considered statistically significant in 
the analysis. Statistical evaluations were performed using 
Stata version 14 (StataCorp LP, College Station, TX).
Role of the funding source
This work was conducted by authors undertaking an inter-
calated degree with the University of Birmingham, and they 
received individual financial bursaries from Kidney Research 
UK and the Arthur Thomson Trust. The funders had no 
role in the design, execution, or analysis of this work.
Data access
All authors have reviewed the final submission, and the cor-
responding author had final responsibility for the submission 
of this article. In line with our Data Sharing Agreement 
with NHS Digital, full access to data remained under the 
sole responsibility of the Department of Health Informatics.
Results
Descriptive analysis for transplant cohort
Between 2003 and 2014, there were 23,984 patients in 
England who had a kidney transplant recorded in our 
administrative dataset. After exclusions (Fig. 1), we had 
a cohort of 19,883 kidney allograft recipients aged 18 
and over for analysis. The cohort was followed to December 
2015, with median follow- up time 6.0 years (or 114,569 
patient- years). Table 1 highlights the descriptive statistics 
of this transplant study cohort.
As our data utilized administration data, we were keen 
to ensure the data were reflective of actual transplantation 
activity. We corroborated our numbers with data from 
the UK Transplant Registry data, where every transplant 
center has a mandatory requirement to register every 
kidney transplant (accessed via the UK National Transplant 
Network). Data corroboration was robust with 95.6% 
concordance (23,984/25,079) between the administrative 
and UK Transplant registry datasets, respectively.
Comparison of post- transplant cancer 
incidence
We identified 1273 kidney allograft recipients (6.40% of 
the transplant patient cohort) who were admitted with a 
new cancer diagnosis post–kidney transplantation. The cor-
responding cancer incident cohort from the general popula-
tion (with at least one hospitalized episode to an English 
hospital with a cancer diagnosis during study period) com-
prised of 1,750,197 persons aged 18 and over, with no 
previous cancer diagnosis or solid organ transplant. Table 2 
shows the raw data for type of cancer comparing the trans-
plant to the general population cohort, highlighting increased 
risk for selected cancers (e.g., lymphoma, kidney) but 
decreased risk for others (e.g., breast, prostrate) post- 
transplantation. The overall standardized incidence ratio 
for cancer incidence was 2.47 (95% CI: 2.34–2.61), con-
firming significantly increased rates of cancer among kidney 
allograft recipients versus the general population, although 
rates varied among different cancers (see Table 3). In both 
the unadjusted Kaplan–Meier curves (see Fig. 2) and the 
adjusted Cox regression analysis (see Table 4), there was 
no difference in the time taken to develop cancer between 
the kidney transplant and general population cohorts.
Figure 1. Transplant study cohort showing exclusions.
• Original transplant study cohort
23,984
• Missing age
<=5 excluded
• Missing sex
<=5 excluded
• Residence recorded outside of England
531 excluded
• Aged under 18
1256 excluded
• Combined organ transplants
1448 excluded
• History of pretransplant cancer
856 excluded
• Final transplant study cohort
19,883
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In a Cox proportional hazards model for cancer inci-
dence post–kidney transplantation, we observed increasing 
age to be strongly associated with the development of 
post- transplant cancer (hazard ratio 1.05, 95% CI: 1.04–
1.05). Other significant risk factors included recipients of 
deceased kidney donors (hazard ratio 1.14, 95% CI: 
1.00–1.30) and increased number of readmissions (greater 
than three) within the first year of transplant (hazard 
ratio 3.58, 95% CI: 2.79–4.58). Repeat kidney transplant 
recipients were at reduced risk of developing post- transplant 
cancer (hazard ratio 0.62. 95% CI: 0.46–0.85).
Mortality risk after development of cancer
Mortality risk for the entire cohort after kidney transplantation 
was 2.83% (n = 562) and 12.38% (n = 2462) after 1 year 
and at any point during follow- up, respectively. Among the 
1273 patients who developed post- transplant cancer (median 
time post- transplant 3.8 years [interquartile range 1.8—
6.2 years]), risk for mortality within 1 year and at any point 
during follow- up was 3.61% and 41.95%, respectively.
Table 3 shows the respective standardized mortality rates 
for the kidney transplant population compared to the general 
population after a diagnosis of cancer. Despite increased 
incidence, risk for cancer- related mortality was actually lower 
for kidney allograft recipients versus the general population 
after development of cancer (standardized mortality ratio 
0.75, 95% CI: 0.71–0.79). In addition, noncancer- related 
mortality was also lower for kidney allograft recipients versus 
the general population after diagnosis of cancer (standard-
ized mortality ratio 0.90, 95% CI: 0.85–0.95). While these 
ratios varied dependent upon cancer site, the overall risk 
for cancer and noncancer- related mortality was lower for 
kidney allograft recipients versus the general population.
Discussion
In this retrospective population cohort study, we have 
compared cancer incidence and progression to mortality 
for kidney allograft recipients compared to the general 
Table 2. Incidence of cancer comparing transplant and general 
 population cohort.
Type of cancer 
category
Transplant cohort 
N (% of total 
cancers)
General population 
cohort 
N (% of total cancers)
Bladder 55 (4.3% 46,890 (2.7%)
Brain 9 (0.7%) 37,850 (2.2%)
Breast 81 (6.4%) 200,481 (11.5%)
Cervix Uteri 10 (0.8%) 15,417 (0.9%)
Colon and Rectum 78 (6.1%) 133,080 (7.6%)
Hodgkin’s Disease 13 (1.0%) 11,003 (0.6%)
Kidney except Renal 
Pelvis
143 (11.2%) 34,808 (2.0%)
Larynx * 7580 (0.4%)
Leukemia 17 (1.3%) 62,942 (3.6%)
Lip Oral Cavity and 
Pharynx
53 (4.2%) 30,213 (1.7%)
Liver and 
Intrahepatic Bile 
Ducts
7 (0.5%) 28,907 (1.7%)
Melanoma of Skin 55 (4.3%) 42,909 (2.5%)
Mesothelioma * 17,619 (1.0%)
Multiple Myeloma 27 (2.1%) 33,082 (1.9%
Non- Hodgkin’s 
Lymphoma
212 (16.7%) 69,079 (3.9%)
Esophagus 20 (1.6%) 58,461 (3.3%)
Other 224 (17.6%) 281,835 (16.1%)
Ovary 9 (0.7%) 35,299 (2.0%
Pancreas 19 (1.5%) 58,625 (3.3%)
Prostate 97 (7.6%) 212,824 (12.2%)
Stomach 22 (1.7%) 46,291 (2.6%)
Testis 6 (0.5%) 13,070 (0.7%)
Thyroid 16 (1.3%) 13,144 (0.8%)
Trachea Bronchus 
and Lung
90 (7.1%) 256,100 (14.6%)
Uterus * 2688 (0.2%)
Total Cancers 1273 (100.0%) 1,750,197 (100.0%)
*Numerically too small to identify.
Table 1. Baseline demographics of the English kidney allograft recipient 
cohort.
Variable
Number of 
Patients
Total number of patients 19,883
Age (years) Mean (SD) 47.55 (13.69)
Post- transplant hospital 
stay (days)
Median (IQR) 7 (5–10)
Sex Male 12,223 (61.47%)
Female 7660 (38.53%)
Index of multiple 
deprivation (multiple 
deprivation index 
comprised from; 
income, employment, 
health, education, 
housing, crime, and 
living environment)
1 (Most deprived) 4530 (22.78%)
2 4320 (21·73%)
3 3892 (19.57%)
4 3547 (17.84%)
5 (Least deprived) 3480 (17.50%)
Unknown 114 (0.57%)
Type of donor Living 7174 (36.08%)
Deceased 12,381 (62.27%)
Unknown 328 (1.65%)
Operation year 2003–2006 5008 (25.19%)
2007–2010 6885 (34.63%)
2011–2014 7990 (40.19%)
Repeat transplant 807 (4.06%)
Ethnic group White 15,351 (77.21%)
Black 1331 (6.69%)
Other 3201 (16.10%)
Charlson comorbidity 
score (renal disease 
excluded)
0 16,194 (81.45%)
1–4 2231 (11.22%)
5+ 1458 (7.33%)
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population using hospital administrative data. In line with 
expectations, we observed an increased incidence of 
cancer after kidney transplantation. However, our data 
paradoxically observed reduced risk for both cancer- related 
and noncancer- related mortality after development of 
cancer for kidney allograft recipients versus the general 
population. The results of our study, which contradict 
published literature of increased cancer- linked mortality 
after transplantation, question the use of hospital admin-
istrative data alone for cancer epidemiology studies and 
its associated methodology.
Cancer rates are known to increase over the spectrum 
of kidney disease but are significantly augmented after 
kidney transplantation [8]. This is predominantly due to 
the contributing risk from immunosuppression, with inci-
dence of cancer almost mirroring those observed in HIV/
AIDS patients [2]. Previous registry data from the United 
Kingdom highlighted double the risk for new- onset cancer 
for transplant recipients versus the general population 
[12], and our analysis also confirms this increased risk 
for cancer after kidney transplantation. Recent work from 
Acuna and colleagues, using data linkage between Canadian 
Table 3. Standardized incidence and mortality ratio after kidney transplantation.
Type of cancer 
category
Cancer incidence (transplant vs. general 
population)
Cancer mortality (transplant vs. 
general population)
Noncancer mortality (transplant vs. 
general population)
SIR (95% CI) SMR (95% CI)
Bladder 5.19 (4.91, 5.48) 0.76 (0.72, 0.80) *
Brain 1.03 (0.97, 1.08) 0.63 (0.59, 0.66) *
Breast 1.00 (0.95, 1.06) 0.97 (0.92, 1.02) 0.54 (0.51, 0.57)
Cervix Uteri 1.84 (1.74, 1.94) 0.40 (0.38, 0.43) *
Colon and Rectum 1.49 (1.41, 1.58) 0.62 (0.59, 0.65) 1.06 (1.00, 1.12)
Hodgkin’s Disease 3.23 (3.06, 3.41) * *
Kidney except Renal 
Pelvis
6.49 (6.14, 6.85) 0.42 (0.39, 0.44) 0.84 (0.79, 0.89)
Larynx * 1.87 (1.77, 1.97) *
Leukemia 1.31 (1.24, 1.39) 0.89 (0.84, 0.94) *
Lip Oral Cavity and 
Pharynx
2.85 (2.70, 3.01) 0.99 (0.94, 1.05) *
Liver and Intrahepatic 
Bile Ducts
0.93 (0.88, 0.99) 1.03 (0.97, 1.09) *
Melanoma of Skin 1.99 (1.88, 2.10) 2.33 (2.21, 2.46) 0.47 (0.45, 0.50)
Mesothelioma * 1.02 (0.97, 1.08) *
Multiple Myeloma 3.74 (3.54, 3.95) 0.76 (0.72, 0.80) *
Non- Hodgkin’s 
Lymphoma
10.12 (9.57, 10.68) 1.00 (0.94, 1.05) 1.12 (1.06, 1.18)
Esophagus 1.55 (1.47, 1.64) 0.87 (0.82, 0.92) *
Other 4.84 (4.57, 5.10) 0.85 (0.81, 0.90) 1.54 (1.46, 1.63)
Ovary 0.92 (0.87, 0.97) 1.53 (1.45, 1.61) *
Pancreas 1.65 (1.56, 1.74) 0.65 (0.61, 0.69) *
Prostate 1.20 (1.13, 1.27) 0.64 (0.61, 0.68) 0.83 (0.79, 0.88)
Stomach 2.88 (2.72, 3.04) 0.80 (0.76, 0.85) *
Testis 0.85 (0.80, 0.90) * *
Thyroid 2.23 (2.11, 2.35) * *
Trachea Bronchus 
and Lung
1.69 (1.60, 1.79) 0.88 (0.83, 0.93) 1.49 (1.41, 1.58)
Uterus * * *
All 2.47 (2.34, 2.61) 0.75 (0.71, 0.79) 0.90 (0.85, 0.95)
*Numerically too small to identify.
Figure 2. Unadjusted Kaplan–Meier plot of time to cancer.
0.
00
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00
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Time to cancer (Years)
General population Transplant cohort
P = 0.5585
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Organ Replacement Register, the Ontario Cancer Registry, 
and the Office of the Registrar General of Ontario, also 
showed increased risk for cancer- specific death for solid 
organ transplant recipients versus the general population 
in Ontario regardless of age, sex, or transplanted organ 
[13]. Our current findings even contradict our previous 
work, also using hospital administrative data, which dem-
onstrated increased risk for cancer- related mortality for 
kidney allograft recipients versus the general population 
in England [5].
However, there are methodological differences between 
these studies and our current analysis. Previous work 
explored risk for cancer- related mortality among all kidney 
allograft recipients, while our current analysis examines 
risk for cancer- related mortality among kidney allograft 
recipients who specifically developed cancer after trans-
plantation. This is an important difference because, being 
aware that cancer incidence is significantly increased after 
kidney transplantation, analyzing cancer- related mortality 
as a proportion of the entire kidney allograft cohort will 
skew the standardized incidence ratio to imply higher 
cancer- related mortality after kidney transplantation versus 
the general population. Standardized cancer mortality ratios 
were observed to be similar between kidney transplant 
and general population cohorts by Kiberd and colleagues, 
in their analysis of the United States Renal Data System 
(study period January 1990 to December 2004) [5]. The 
authors suggested cancer- related mortality rates were simi-
lar due to possible competing risks for death after kidney 
transplantation but failed to explore this further. Our 
study explores this for the first time and demonstrates a 
significantly lower risk for noncancer- related mortality 
after development of cancer for kidney allograft recipients 
versus the nontransplant population. We can speculate 
that cancer is diagnosed earlier for kidney allograft recipi-
ents, due to their close lifelong supervision under the 
specialist care of nephrologists. Supporting this notion is 
data from Cho and colleagues, analyzing the Surveillance, 
Epidemiology, and End Results (SEER) program, who 
observed noncancer- related survival was higher for patients 
diagnosed with early cancer versus the matched US general 
population, while the reciprocal was true for advanced 
cancer [20]. This would fit in with the observation from 
Table 3, which suggests the most incident post- transplant 
cancers appear to have the greater survival benefit. However, 
identifying less noncancer- related mortality for kidney 
transplant recipients who develop cancer seems implausible 
considering the burden of complications associated with 
long- term immunosuppression.
The progressive risk of cancer from incidence to mor-
tality has been reported in the general population. Jemal 
et al. [21] reviewed cancer incidence and mortality from 
global population- based cancer incidence data and observed 
disparate epidemiological patterns. While cancer rates for 
malignancies commonly attributed to developed countries 
(e.g., lung, colorectal, breast) are falling, their rates are 
increasing in the developing world. In addition, infection- 
related cancers (e.g., cervical, liver, digestive organs) con-
tinue to disproportionately affect developing countries. 
This latter point is important for our study as cancers 
secondary to an infectious etiology predominate after 
kidney transplantation, with kidney cancers the exception. 
This was shown in the study from Grulich and colleagues, 
where cancer incidence for kidney allograft recipients was 
broadly on a par with comparable immune deficiency 
states such as HIV/AIDS [2]. The etiology of cancer 
 post- transplantation is primarily driven by the effects of 
immunosuppression, with suggestions of an important 
interplay with viral pathogens that contribute to 
 pathophysiology [22]. While we did not have access to 
immunosuppression regimen data in our analysis, recent 
data would suggest similar carcinogenicity among different 
immunosuppressant regimens [23] meaning there should 
be minimal confounding from different immunosuppres-
sion regimens in use across England.
The likeliest explanation for our data is the inaccuracy 
of cancer- related outcomes in hospital administrative data. 
However, the paradoxical data in our analysis reflect the 
Table 4. Cox regression analysis of time to cancer comparing transplant and general population cohort.
Variable Hazard ratio (95% CI) P- value
Age 1.00 (1.00–1.01) 0.012
Sex Male 1 (baseline group)
Female 1.02 (0.94–1.10) 0.715
Ethnic group White 1 (baseline group)
Black 1.16 (0.96–1.41) 0.121
Other 1.04 (0.95–1.15) 0.367
Charlson comorbidity category 0 1 (baseline group)
1–4 0.96 (0.85–1.08) 0.510
5+ 1.07 (0.98–1.63) 0.142
Cohort Transplant 1 (baseline group)
General population 1.04 (0.96–1.14) 0.299
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standardized mortality ratio rather than the incidence ratio. 
We would anticipate the latter being underrepresented 
by hospital administrative data as only hospitalized data 
would be captured. Therefore, cancers not requiring hos-
pital admission (e.g., little treatment potential or outpatient 
management sufficient) will not be captured. However, 
mortality events should be robustly captured using linkage 
of the Hospital Episode Statistics to the Office for National 
Statistics which capture all deaths. Therefore, our para-
doxical findings of lower cancer and noncancer mortality 
events among kidney transplant recipients seem puzzling. 
While contradictory to published literature and registry 
reports, there could be some plausible explanations for 
our findings. Cancer survival may be better due to earlier 
diagnosis after kidney transplantation due to close super-
vision and heightened risk awareness. In addition, cancer 
management after kidney transplantation frequently 
involves tapering of immunosuppression, which may be 
more effective than conventional treatment alone at attenu-
ation of cancer- related mortality. Reduced noncancer 
mortality may be secondary to aggressive medical man-
agement by transplant clinicians, with patients remaining 
under lifelong surveillance and supervision of secondary 
care specialists. However, increased cardiovascular- related 
mortality is generally noted for kidney allograft recipients 
versus the general population [24] and reasserts the para-
doxical nature of our results. Kidney allograft recipients 
may be more compliant with national screening protocols, 
although robust evidence- base for optimal screening pro-
tocols are lacking [25, 26], and recent evidence from a 
Canadian transplant cohort in fact suggests kidney trans-
plant recipients have worse adherence to cancer screening 
programs compared to the general population [27].
The linkage of the large HES administrative dataset 
of secondary care to official mortality data held by ONS 
ensures generalizability and applicability to the wider 
transplant community. While this ensures the robustness 
of our findings, we have several limitations to acknowl-
edge which may influence our results. The biggest limita-
tion is that cancer registration will be underestimated 
using HES data rather than dedicated cancer registry data 
as it only identifies patients hospitalized with cancer codes. 
This is consistent with a study from the United States 
showing cancer information from administration data is 
substantially incomplete in relation to cancer registries 
[28]. Administrative and registry data have well- 
documented limitations, both generally [29] and in the 
context of solid organ transplantation [14], that lead to 
inherent problems with such analyzes. There will be sig-
nificant confounding from lead- time bias, as first docu-
mented cancer episode may not necessarily represent the 
initial cancer diagnosis with a false impression of survival 
subsequently assumed. From a HES perspective, our 
analysis of the cancer incidence ratio is skewed against 
cancers not likely to lead to a hospitalization episode 
(i.e., nonmelanoma skin cancers which are the most com-
monly occurring cancers after kidney transplantation). 
We therefore opted to omit all nonmelanoma skin cancer 
from our analysis as they are least likely to cause death 
[5, 6, 13] and will have little impact upon our mortality 
observations. The hospitalized general population cohort 
could have a greater burden of health comorbidities that 
has skewed comparisons with kidney transplant recipients, 
leading to the paradoxical survival outcomes for the lat-
ter. We attempted to correct for the general population 
confounder by calculating standardized incidence and 
mortality ratios of the hospitalized general population 
cohort using life-table ratios for the adult general popula-
tion. The lack of information on renal and transplant- 
specific factors, available from the UK Renal and Transplant 
Registry, respectively, is important as they can impact 
upon cancer- related epidemiology (e.g., dialysis vintage, 
kidney rejection and/or failure). A deeper probe of this 
cohort will require analysis of cancer stages, grading 
and management (available from cancer registries) and 
linkage to primary care data resources to obtain informa-
tion regarding prescriptions (especially immunosuppres-
sion). The Epidemiology of Cancer after Solid 
Organ Transplantation (EpCOT) project, by facilitating 
record linkage between these different national registries 
(e.g., transplant, cancer, hospital administration, mortal-
ity) for all solid organ transplant recipients in England, 
should provide a more comprehensive analysis to answer 
the unanswered questions from this analysis (clinicaltrials.
org identifier—NCT02991105).
To conclude, our population cohort study of kidney 
allograft recipients in England has demonstrated an 
increased risk for developing cancer compared to the 
general population consistent with the published literature. 
However, after development of cancer, our data suggest 
kidney allograft recipients have reduced risk for both 
cancer and noncancer- related mortality compared to the 
general population. This paradoxical finding is unlikely 
to be plausible and suggests limitations with relying upon 
hospital administrative data for cancer- related epidemio-
logical studies. The limitations from our analysis suggest 
comprehensive studies on this issue will require robust 
record linkage between numerous data registries to truly 
establish our understanding of the risk of mortality for 
kidney transplant recipients after they develop cancer.
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